Nerve damage and stomach emptying problems in diabetes patients taking semaglutide
Compares gastric retention in diabetic patients on semaglutide, with and without neuropathy.
Key facts
- Who runs it
- Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
- Status
- Not yet recruiting
- People taking part
- 460 people, planned
- Started
- 15 Sept 2025
- Expected to end
- 15 Sept 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Esophagogastroduodenoscopy
- Record updated
- 5 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes who take semaglutide and are having a stomach scope (gastroscopy). It compares people with nerve damage (neuropathy) and people without it.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Confirmed diabetes. General health class ASA I-II (healthy or mild disease that is under control). Neuropathy status checked within 2 weeks before gastroscopy.
- Earlier treatment
- Must have used semaglutide for at least 4 weeks without stopping before the scope. Must fast at least 8 hours and drink no water for at least 4 hours before gastroscopy.
Main reasons for not taking part
- Hiatal hernia (part of the stomach pushes up into the chest)
- Any past stomach surgery, such as gastrectomy or Roux-en-Y gastric bypass
- Pregnancy
- Not fit enough for a stomach scope
- Judged by the study doctors as unable to take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Confirmed diagnosis of diabetes mellitus
- Long-term use of semaglutide (for at least 4 weeks) without discontinuation prior to endoscopic examination
- Age ≥ 18 years, with no restriction on sex
- American Society of Anesthesiologists (ASA) physical status classification I-II
- Fasting for at least 8 hours and no water intake for at least 4 hours prior to gastroscopy
- Underwent assessment for both autonomic and peripheral neuropathy within 2 weeks prior to gastroscopy, with a clear determination of neuropathy status
Who cannot take part
- History of hiatal hernia or any prior gastric surgery (including gastrectomy, Roux-en-Y gastric bypass, etc.)
- Pregnancy
- Medically unfit for gastrointestinal endoscopy
- Deemed unsuitable for participation at the discretion of the investigators
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted semaglutide therapy
The 2 groups in the trial
- Exposure group
Diabetic patients with neuropathy receiving uninterrupted semaglutide therapy
Treatment: Esophagogastroduodenoscopy
- Non-exposure group
Diabetic patients without neuropathy receiving uninterrupted semaglutide therapy
Treatment: Esophagogastroduodenoscopy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention: A Single-Center, Prospective, Observational Study
- Plain-language title
- Nerve damage and stomach emptying problems in diabetes patients taking semaglutideGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 5 September 2025